LAG-3 checkpoint inhibitor (Suzhou Transcenta Therapeutics)

N/A

Report date: 2025/03/20 14:49:25

Base Information

Drug NameLAG-3 checkpoint inhibitor (Suzhou Transcenta Therapeutics)
Drug Alias Nameanti-LAG-3 mAb (Suzhou Transcenta Therapeutics)pH-dependent LAG-3 antibody (Suzhou Transcenta Therapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitors
TargetsLymphocyte activation gene 3 protein
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSuzhou Transcenta Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Transcenta Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A